Commit Biologics secures €16m seed funding for its Bispecific Complement Engaging (BiCE) platform to treat cancer and autoimmune diseases.
Commit Biologics raises €16m seed funding from Bioqube Ventures and Novo Holdings to advance its Bispecific Complement Engaging (BiCE) platform, a novel approach to activate the complement component of the immune system for treating cancer and autoimmune diseases. The platform uses single domain antibodies to bind the complement protein C1q, activating the complement system to selectively kill target cells.
May 09, 2024
4 Articles